Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorder and serious mental illnesses.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDIVIOR HIT HARD AS GENERIC SUBOXONE DEFENCE CRUMBLES

Pharmaphorum Media Limited | November 22, 2018

news image

Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares. The UK company’s attempt to block a generic version of Suboxone Film (sublingual buprenorphine/naloxone) developed by India’s Dr. Reddy’s Laboratories has been rejected by an appeals court, upholding an earlier ruling of non-infringement of a key patent on the brand.Dr. Reddy’s said in a statem...

Read More

INDIVIORS FORMER PARENT PONIES UP A WHOPPING $1.4B TO SETTLE SUBOXONE MARKETING PROBE

fiercepharma | July 11, 2019

news image

With the feds sniffing around Indiviors aggressive marketing of its opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker. The stink was bad enough that Indivior’s former parent company is paying a steep price to clear its name—to the tune of $1.4 billion. Reckitt Benckiser settled with the Justice Department and Federal Trade Commission for $1.4 billion Thursday to end multiple federal probes into an alleged scheme to push sales of the opioid addiction tre...

Read More

Business Insights

INDIVIOR TO ACQUIRE OPIANT PHARMACEUTICALS

Indivior | November 21, 2022

news image

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...

Read More

Business Insights, PHARMA TECH

INDIVIOR ANNOUNCES ITS SUCCESSFUL ACQUISITION OF OPIANT PHARMACEUTICALS

Indivior | March 06, 2023

news image

Indivior PLC, a global pharmaceutical company, recently announced its successful acquisition of Opiant Pharmaceuticals, Inc. The acquisition strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets. In particular, OPNT003, an investigational opioid overdose treatment, aims to provide an effective treatment option to address the current wave of opioid overdose caused by powerful synthetic opioids such as fentanyl. Indivior acqu...

Read More
news image

INDIVIOR HIT HARD AS GENERIC SUBOXONE DEFENCE CRUMBLES

Pharmaphorum Media Limited | November 22, 2018

Indivior has suffered a critical defeat in the US courts for opioid addiction product Suboxone Film, opening the door to generic competition and sparking a run on its shares. The UK company’s attempt to block a generic version of Suboxone Film (sublingual buprenorphine/naloxone) developed by India’s Dr. Reddy’s Laboratories has been rejected by an appeals court, upholding an earlier ruling of non-infringement of a key patent on the brand.Dr. Reddy’s said in a statem...

Read More
news image

INDIVIORS FORMER PARENT PONIES UP A WHOPPING $1.4B TO SETTLE SUBOXONE MARKETING PROBE

fiercepharma | July 11, 2019

With the feds sniffing around Indiviors aggressive marketing of its opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker. The stink was bad enough that Indivior’s former parent company is paying a steep price to clear its name—to the tune of $1.4 billion. Reckitt Benckiser settled with the Justice Department and Federal Trade Commission for $1.4 billion Thursday to end multiple federal probes into an alleged scheme to push sales of the opioid addiction tre...

Read More
news image

Business Insights

INDIVIOR TO ACQUIRE OPIANT PHARMACEUTICALS

Indivior | November 21, 2022

Indivior PLC and Opiant Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Indivior will acquire Opiant for an upfront consideration of $20.00 per share, in cash plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch. The transaction has been unanimously approved by the boards of di...

Read More
news image

Business Insights, PHARMA TECH

INDIVIOR ANNOUNCES ITS SUCCESSFUL ACQUISITION OF OPIANT PHARMACEUTICALS

Indivior | March 06, 2023

Indivior PLC, a global pharmaceutical company, recently announced its successful acquisition of Opiant Pharmaceuticals, Inc. The acquisition strengthens Indivior's addiction treatment and science portfolio by adding Opiant's late-stage assets. In particular, OPNT003, an investigational opioid overdose treatment, aims to provide an effective treatment option to address the current wave of opioid overdose caused by powerful synthetic opioids such as fentanyl. Indivior acqu...

Read More